Stocks making the biggest moves premarket: Robinhood, Amazon, Apple, Roku and more

Stocks making the biggest moves premarket: Robinhood, Amazon, Apple, Roku and more


Vlad Tenev, CEO and co-founder Robinhood Markets, Inc., is displayed on a screen during his company’s IPO at the Nasdaq Market site in Times Square in New York City, U.S., July 29, 2021.

Brendan McDermid | Reuters

Check out the companies making headlines in premarket trading Friday.

Apple — Apple’s stock price dipped 2% after CFO Luca Maestri said supply chain issues would hurt third-quarter sales by as much as $8 billion. Still, many analysts on Wall Street remained positive on the company after its recent earnings report that topped expectations. One analyst said any weakness in the stock is a buying opportunity.

Amazon — Shares dropped more than 9% after Amazon disclosed weaker-than-expected revenue guidance for the second quarter. The tech giant also posted a $7.6 billion loss on its investment into Rivian, which lost more than half its value in the quarter.

Roku — Shares of Roku popped more than 4% after the digital media player manufacturer on Thursday reported sales that exceeded expectations in its recent quarter. Roku posted a revenue of $733.7 million. Analysts polled by Refinitiv were expecting $718 million.

Intel — Shares fell more than 3% after Intel issued weak guidance for its fiscal second quarter, overshadowing stronger-than-expected earnings for the previous quarter.

Robinhood — The retail brokerage stock dropped nearly 10% following a first-quarter report that showed declining revenue and monthly active users. CEO Vlad Tenev said that the company saw its customers with smaller accounts trade less when the market fell.

Alibaba, Pinduoduo, Baidu — Chinese technology stocks surged after policymakers in the country signaled an easing of the crackdown on tech companies. Alibaba rallied more than 10%, Pinduoduo soared 15% and Baidu jumped more than 8%.

Bristol-Myers Squibb — The biopharmaceutical stock dipped 1.5% despite an earnings report that topped expectations. On Friday, Bristol-Myers Squibb disclosed it earned $1.96 per share on revenues of $11.65 billion. The company was forecasted to earn $1.91 per share on revenues of $11.36 billion, according to Refinitiv.

Honeywell International — Shares jumped 2% after Honeywell reported earnings that surpassed expectations. Honeywell posted earnings of $1.91 per share on revenues of $8.38 billion. Meanwhile, analysts surveyed by Refinitiv were forecasting $1.86 earnings per share on revenues of $8.29 billion.

Chevron — Shares dipped 1% even after Chevron posted better-than-expected results for the previous quarter. Chevron posted earnings per share of $3.36 per share on revenues of $54.37 billion. Analysts polled by Refinitiv were expecting $3.27 earnings per share on revenues of $47.94 billion.

Exxon Mobil — Exxon Mobil’s stock price dipped 1% after the oil and gas company reported weaker-than-expected quarterly results. The energy company earned $2.07 per share, lower than Refinitiv estimates of $2.12 earnings per share. Exxon Mobil reported revenues of $90.5 billion, compared to a Refinitiv forecast of $92.7 billion.

— CNBC’s Hannah Miao and Jesse Pound contributed reporting.



Source

Historic winter storms weigh on Gap, Old Navy performance after 800 temporary store closures
Business

Historic winter storms weigh on Gap, Old Navy performance after 800 temporary store closures

Pedestrians in the snow at Times Square during a winter storm in New York, US, on Sunday, Feb. 22, 2026. Bloomberg | Bloomberg | Getty Images Historic winter storms and subsequent store closures weighed on Gap’s performance during its holiday quarter and contributed to worse-than-expected results at its portfolio of brands, the retailer said Thursday.  […]

Read More
FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease
Business

FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease

Thomas Fuller | SOPA Images | Lightrocket | Getty Images UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday. The official, who requested anonymity before discussing sensitive information, confirmed the agency […]

Read More
Home sellers are relisting properties at fastest pace in a decade, but spring supply is still low
Business

Home sellers are relisting properties at fastest pace in a decade, but spring supply is still low

A “For Sale” sign outside a house in the Capitol Hill neighborhood of Washington, DC, US, on Tuesday, Aug. 12, 2025. Al Drago | Bloomberg | Getty Images The all-important spring housing market is off and running, and while the pace isn’t expected to be strong, there are signs of optimism, at least among sellers. […]

Read More